ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21 USD | +11.29% |
|
+5.69% | -1.96% |
| Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 440.9 | 588 | 960.7 | 881.1 | 569.2 | 573.7 | - | - |
| Enterprise Value (EV) 1 | 68.07 | 194.3 | 412.6 | 439.9 | 151.3 | 290.6 | 257.9 | 573.7 |
| P/E ratio | -4.51 x | -29.5 x | -16.5 x | -6.78 x | -3.52 x | -3.32 x | -3.58 x | -3.56 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 55.1 x | 7.84 x | 15.2 x | 85.7 x | 33.2 x | 35 x | 22.4 x | 20.2 x |
| EV / Revenue | 8.51 x | 2.59 x | 6.53 x | 42.8 x | 8.82 x | 17.7 x | 10.1 x | 20.2 x |
| EV / EBITDA | -0.64 x | -8.33 x | -7.34 x | -3.84 x | -0.92 x | -1.66 x | -1.62 x | - |
| EV / FCF | -0.97 x | -13.2 x | -8.72 x | -5.95 x | -1.24 x | -3.67 x | -1.97 x | -2.12 x |
| FCF Yield | -103% | -7.58% | -11.5% | -16.8% | -80.4% | -27.3% | -50.8% | -47.1% |
| Price to Book | 1.09 x | 1.48 x | 2.7 x | 3.37 x | 6.93 x | -14.9 x | -6.84 x | - |
| Nbr of stocks (in thousands) | 27,133 | 27,348 | 27,645 | 28,432 | 26,575 | 27,319 | - | - |
| Reference price 2 | 16.25 | 21.50 | 34.75 | 30.99 | 21.42 | 21.00 | 21.00 | 21.00 |
| Announcement Date | 3/2/20 | 2/25/21 | 3/7/22 | 3/1/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8 | 75 | 63.18 | 10.29 | 17.16 | 16.39 | 25.59 | 28.39 |
| EBITDA 1 | -106.9 | -23.32 | -56.2 | -114.5 | -163.8 | -175.1 | -158.8 | - |
| EBIT 1 | -107.4 | -23.88 | -56.81 | -115.2 | -164.4 | -177.7 | -188.5 | -221.3 |
| Operating Margin | -1,342.9% | -31.84% | -89.93% | -1,119.41% | -958.27% | -1,084.69% | -736.69% | -779.61% |
| Earnings before Tax (EBT) 1 | -97.49 | -19.93 | -57.8 | -128.7 | -163.6 | -180.7 | -193.3 | -222.4 |
| Net income 1 | -97.34 | -20.27 | -57.8 | -128.7 | -163.6 | -178.1 | -196.4 | -227.1 |
| Net margin | -1,216.7% | -27.03% | -91.49% | -1,251.33% | -953.66% | -1,086.84% | -767.45% | -799.9% |
| EPS 2 | -3.600 | -0.7300 | -2.110 | -4.570 | -6.080 | -6.320 | -5.867 | -5.899 |
| Free Cash Flow 1 | -70.32 | -14.73 | -47.29 | -73.95 | -121.6 | -79.24 | -130.9 | -270 |
| FCF margin | -879.02% | -19.63% | -74.85% | -718.88% | -708.79% | -483.64% | -511.41% | -951.18% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/25/21 | 3/7/22 | 3/1/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.89 | 1.011 | 0.97 | 1.216 | 1.293 | 6.808 | 1.374 | 3.46 | 3.318 | 9.005 | 3.442 | 3.891 | 4.396 | 4.628 | 7.275 |
| EBITDA 1 | -6.594 | -30.99 | -31.59 | -27.64 | -29.47 | -25.79 | -44.24 | -39.98 | - | -41.97 | -47 | -46 | -45 | -43 | - |
| EBIT 1 | -6.763 | -31.16 | -31.75 | -27.8 | -29.63 | -25.97 | -44.4 | -40.14 | -37.73 | -42.14 | -42.59 | -43.78 | -44.85 | -46.46 | -45.65 |
| Operating Margin | -32.37% | -3,081.8% | -3,273.09% | -2,286.1% | -2,291.8% | -381.51% | -3,231.51% | -1,160.2% | -1,137.19% | -467.91% | -1,237.44% | -1,125.29% | -1,020.21% | -1,003.87% | -627.51% |
| Earnings before Tax (EBT) 1 | -6.666 | -32.54 | -36.26 | -32.55 | -33.5 | -26.39 | -44.26 | -39.84 | -37.31 | -42.22 | -42.97 | -44.37 | -45.86 | -47.38 | -42.7 |
| Net income 1 | -6.666 | -32.54 | -36.26 | -32.55 | -33.5 | -26.41 | -44.26 | -39.84 | -37.31 | -42.21 | -42.48 | -43.89 | -45.16 | -46.47 | -44 |
| Net margin | -31.91% | -3,218.4% | -3,737.63% | -2,677.14% | -2,591.03% | -387.97% | -3,220.89% | -1,151.59% | -1,124.41% | -468.75% | -1,234.28% | -1,128% | -1,027.39% | -1,004.07% | -604.83% |
| EPS 2 | -0.2400 | -1.180 | -1.310 | -1.150 | -1.180 | -0.9300 | -1.580 | -1.500 | -1.410 | -1.590 | -1.583 | -1.624 | -1.565 | -1.579 | -1.660 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/7/22 | 5/4/22 | 8/8/22 | 11/8/22 | 3/1/23 | 5/11/23 | 8/7/23 | 11/2/23 | 3/11/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 373 | 394 | 548 | 441 | 418 | 283 | 316 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -70.3 | -14.7 | -47.3 | -74 | -122 | -79.2 | -131 | -270 |
| ROE (net income / shareholders' equity) | -21.8% | -5.06% | -15.3% | -41.6% | -93.4% | -511% | - | - |
| ROA (Net income/ Total Assets) | -20.6% | -4.76% | -10.9% | -20.5% | -30.8% | -49.6% | -56.1% | - |
| Assets 1 | 472.1 | 425.9 | 529.8 | 626.7 | 531.4 | 358.8 | 350.4 | - |
| Book Value Per Share 2 | 14.90 | 14.50 | 12.90 | 9.190 | 3.090 | -1.410 | -3.070 | - |
| Cash Flow per Share | - | -0.5200 | - | - | - | - | - | - |
| Capex 1 | 0.81 | 0.57 | 1.37 | 0.36 | 0.81 | 1.16 | 1.29 | 1 |
| Capex / Sales | 10.06% | 0.76% | 2.16% | 3.48% | 4.7% | 7.06% | 5.06% | 3.52% |
| Announcement Date | 3/2/20 | 2/25/21 | 3/7/22 | 3/1/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
21
USD
Average target price
43.5
USD
Spread / Average Target
+107.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.96% | 574M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ANAB Stock
- Financials AnaptysBio, Inc.
